Summary
Quantum BioPharma Ltd. (QNTM) Business Update Conference Call Transcript
Call Start: 16:30 January 1, 0000 4:57 PM ET Quantum BioPharma Ltd. (NASDAQ:QNTM ) Business Update Conference Call May 6, 2025, 04:30 PM ET Company Participants Zeeshan Saeed - Founder, Chief Executive Officer, President and Executive Co-Chair Jason Sawyer - Head of Finance and M&A Conference Call Participants Operator Greetings, and welcome to the Quantum BioPharma Business Update Conference Call.
Overlooked Stock: QNTM
Quantum's in the name but has no part of the business. Quantum BioPharma (QNTM) is up over 130% year to date but has fallen more than 50% off its all-time high.
Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders TORONTO, ON / ACCESSWIRE / October 21, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces the Company, on 20th October 2024, has filed a complaint in the United States District Court for the Southern District of New York alleging that CIBC World Markets (CIBC), RBC Dominion Securities (RBC), and others (the "Defendants") engaged in market manipulation schemes that violated Section 10(b) and Rule 10b-5(a) and (c) and Section 9(a) of the Securities Exchange Act of 1934.
Quantum BioPharma Ltd. (QNTM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Quantum BioPharma Ltd. ever had a stock split?
Quantum BioPharma Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Zeeshan Saeed CEO | NASDAQ (CM) Exchange | CA74764Y2050 ISIN |
| CA Country | 17 Employees | - Last Dividend | 15 Aug 2024 Last Split | - IPO Date |
Overview
Quantum BioPharma Ltd. is an innovative biopharmaceutical company dedicated to the discovery and development of novel therapeutics for neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders. Focused on addressing some of the most challenging medical conditions, the company's approach combines cutting-edge research with strategic investments to propel its portfolio of drug candidates through different stages of development. With its headquarters in Toronto, Canada, Quantum BioPharma operates in two primary segments: Biopharmaceutical, which encompasses its research and development activities, and Strategic Investments, through which it manages a portfolio including loans secured by residential property. Originally known as FSD Pharma Inc., the company renamed to Quantum BioPharma Ltd. in August 2024, marking a new phase in its mission to revolutionize patient care in its target therapeutic areas.
Products and Services
Quantum BioPharma Ltd. is developing a diverse portfolio of products and services designed to meet urgent healthcare needs:
- Lucid-MS: This lead compound represents a significant advance in the treatment of Multiple Sclerosis (MS). It is a patented new chemical entity currently in Phase 2 clinical trials. Lucid-MS has shown promise in preventing and reversing myelin degradation, which is a fundamental cause of MS, in preclinical models. By targeting the underlying mechanism of the disease, Lucid-MS has the potential to offer a groundbreaking treatment option for patients suffering from this debilitating condition.
- Treatment for Alcohol Misuse Disorders: Addressing the critical need for effective interventions in alcohol misuse, Quantum BioPharma is developing a novel treatment aimed at hospitals and medical practices. This initiative reflects the company's commitment to expanding its therapeutic reach into areas of high unmet medical need, providing new hope for individuals struggling with alcohol dependency.
- Strategic Investments: Beyond its biopharmaceutical endeavors, Quantum BioPharma maintains a strategic investment portfolio. This includes loans secured by residential property, diversifying the company’s assets and providing a financial foundation to support its core mission in drug development. These investments represent a prudent approach to sustaining the company’s growth and ensuring the continued advancement of its therapeutic pipeline.
Contact Information
